SCHEMBL3664429

SCHEMBL3664429

CCOC(=O)N1CCn2c(nc(-c3ccncc3)cc2=O)C(NC(=O)c2ccc(F)cc2OC)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 10/20 0.43
CYP2D6 P10635 2/20 0.41
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
P2RY12 Q9H244 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
HPGD P15428 1/20 0.37
CDC7 O00311 1/20 0.37
ROCK2 O75116 1/20 0.37
PIM1 P11309 1/20 0.37
HIPK2 Q9H2X6 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3667749 0.92 HPGD (0.40) GSK3BALDH1A1KDM4EKMT2AP2RY12
SCHEMBL3662763 0.88 GSK3B (0.49) GSK3BCYP2D6
SCHEMBL2066786 0.87 GSK3B (0.47) GSK3BCYP2D6MEN1KMT2AHCRTR1
SCHEMBL3660413 0.87 KCNMA1 (0.41) GSK3BALDH1A1P2RY12SMN1; SMN2LMNA
SCHEMBL2064820 0.86 GSK3B (0.48) GSK3BCYP2D6HCRTR1HCRTR2
SCHEMBL2065579 0.86 GSK3B (0.46) GSK3BCYP2D6ALDH1A1MEN1KMT2A
SCHEMBL3657923 0.82 NOS1 (0.44) GSK3BCYP2D6ALDH1A1KDM4EP2RY12
SCHEMBL3397799 0.82 GSK3B (0.44) GSK3BCYP2D6HCRTR1HCRTR2
SCHEMBL3664584 0.82 GSK3B (0.46) GSK3BCYP2D6MEN1KMT2ALMNA
SCHEMBL3662679 0.82 GSK3B (0.44) GSK3BCYP2D6ALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2238141-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA Sanofi-Aventis (FR) 2010-10-13 EP claimed
WO-2009095789-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA SANOFI-AVENTIS (FR) 2009-08-06 WO claimed